First Quarter Financial Summary for the 27th Term | July 31, 2026

Overview of Performance

Azone's first quarter of the 2026 fiscal year recorded sales of 30,002 million yen (up 17.0% YoY), operating income of 10,220 million yen (up 22.6% YoY), and net income of 8,870 million yen (down 2.3% YoY), with significant growth in both sales and operating income. Despite a slight decrease in net income, the company continues to maintain solid performance. The increase in sales is attributed to expanded sales of medical and research equipment and the acquisition of new customers. Cost management and operational efficiencies also contributed to profit expansion.

Outlook and Impact on Investors

Looking ahead, ongoing growth in the medical and research sectors is expected to drive further increases in sales and profits. Demand for research instruments and medical supplies remains robust, forming a stable growth foundation. Improved profitability is anticipated through strict cost control and new product launches. For investors, the company's steady growth and stable earnings make it a promising mid- to long-term investment opportunity.